Expert Commentary | FDA Mid-Cycle Review For Sofpironium Bromide
BOT Video – not to be missed - Here
We’ve united three experts to explain why our lead product, Sofpironium Bromide, is on track to define the success of #Botanix this quarter.Hear from one of the most highly experienced dermatology specialists - former head of the American Academy of Dermatology and Founding President of the International Hyperhidrosis Society, Prof. David Pariser; together with Triangle Insights Group Partner and respected markets commentator, Gautam Aggarwal; and Botanix Chief Operating Officer, Dr. Howie McKibbon.Together, they explain the scope of the market opportunity that Botanix is chasing for Sofpironium Bromide and how this product could positively impact peoples’ lives
Ann: Confirmation Sofpironium Bromide NDA Formally Under Review, page-58
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
-0.005(1.39%) |
Mkt cap ! $642.5M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 35.0¢ | $1.693M | 4.721M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 40362 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 50704 | 1 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |